Not all CBD oils are created equal!
At Vita Botanica, we have incorporated a patented Nanotechnology into our CBD oils that has been clinically proven to significantly increase absorption of CBD into your bloodstream compared to standard oils.
When ingested, most CBD molecules do not make it past the harsh, acidic environment of the stomach. Only 6-19% of CBD reaches the bloodstream, and the remaining 80% (and more!) passes directly out of the body as waste.
Our patented Nanotechnology elevates these absorption rates up to 94% - ensuring the CBD molecules safely reach the sites of action in the body. Our oils deliver greater bioavailability (the amount of CBD that gets into our body) so it can get to work faster and more efficiently, with less broken down and wasted CBD.
What is nanotechnology?
Nanotechnology is science, engineering, and technology conducted at the nanoscale, which is about 1 to 100 nanometers. To give a scale of size, a single sheet of newspaper is 100,000nm thick.
What is nano CBD?
In a nutshell, it is a highly efficient delivery system that enables superior absorption and distribution of CBD into and around the body, thereby making our oils more effective, with less waste.
Why is that important?
There are two reasons why we have incorporated nanotechnology into our CBD oils:
1. The body possesses natural barriers, including harsh stomach acids and enzymes, that break down many molecules, including CBD. As a result, only 6-19% of CBD oils reach our bloodstream - which is a requirement in order to distribute around the body.
2. The body is made up of approximately 60% water, whereas CBD is extracted from the plant in oil form, meaning CBD is a very difficult molecule to deal with. Why? As we all know, oils are hydrophobic, meaning they don't mix with water.
By emulsifying CBD oil into nano-sized particles, our oils generate better dispersion with water so the oil doesn’t aggregate and separate out. We also have oils that are both water-soluble oils and nano emulsified - win-win - which can be dropped into any drinks or mixtures (coffee/tea/water/juice/shakes).
As mentioned above, our patented nanotechnology facilitates superior absorption rates of up to 94%, compared to the typical 6-19%, by emulsifying large, difficult-to-absorb CBD molecules to more dispersible nano-sized CBD molecules. More CBD therefore gets into our bloodstream, thereby distributing around the body to interact with the various tissues and systems.
What are the benefits of nano CBD?
* Elevated absorption and bioavailability due to a superior delivery system, meaning more CBD gets into your body. Raising absorption from 15% up to 90% !!
* Effective distribution of CBD throughout the body, hitting all the target areas
* Speed of delivery significantly increased – almost immediate compared to hours or days
* Better bang for your buck, as less CBD equals the same effectiveness, as well as wasted/broken down CBD significantly reduced
* Oils are more stable, leading to longer shelf life than typical CBD oils
History of nanotechnology
Nanotechnology is the manipulation of atoms, molecules, and supramolecular formations to reduce their scale to between 1 and 100 nanometers (nm). To give a scale of size, a single sheet of paper is 100,000nm thick.
It wasn’t until 1959 when the first ideas of nanotechnology were delivered by physicist Dr. Richard Feynman of the California Institute of Technology (CalTech). He described the reality of “controlling individual atoms and molecules”.
However it wasn’t until 1981 with the invention of scanning tunneling microscopes before we could actually see the nano particles we were forming; this is the first example of practical nanoscience.
Today, scientists, physicians, and engineers are becoming very familiar with reducing the size of atoms, molecules… and yes, even medical devices to nanoscale. Nanoscience is receiving much attention due to its potential roles in pharmaceuticals, biotechnology and medical devices, whereby we can now enhance the properties of many particles and devices to achieve 100% bioavailability (this means 100% of the compound reaches the bloodstream instead of being broken down, lost and wasted) of organic plant nutrients like CBD.
Other nanotechnology examples include medical devices becoming much smaller and lighter in weight, as well as having greater control of chemical interactiveness and stability.
The problem with the current CBD industry is that manufacturing CBD is not quite as simple as adding CBD to a carrier oil, for example MCT (coconut) oil, and placing a brand’s attractive label on it - this is the case for most brands! This means the composition of most CBD products are actually identical - similar to “generics” in the pharmaceutical world.
This is (almost) understandable as CBD is very difficult to work with, however coming from a background of science, manufacturing and biotechnology, we wanted our products to be at the forefront of innovation! So what did owe do to combat this? We incorporated nanotechnology into our oils, which, as mentioned above, has significantly more benefits than the standard off-the-shelf CBD oils that have recently flooded the market!
Please feel free to contact us if you have any questions or queries, we are always happy to help (and also understand it’s not so easy to wrap your head around!).
11. Devinsky, O., M.M. Cilo, H. Cross, J. Fernandez Ruiz, J. French, C. Hill, R. Katz, V. Di Marzo, D. Justras Aswad, W. G. Notcutt, J. Maartinez Orgado, P. J. Robson, B. G. Rohrback, E. Thiele, B. Whalley, and D. Friedman 2014 Cannabidiol Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Epilepsia 55 6 791 802.
12. Atsmon J D. Heffetz, L. Deutsch, F. Deutsch, and H, Sacks. 2017. Single dose pharmacokinetics of oral cannabidiol following administration of PTL 101. A new formulation based on gelatin matrix pellets technology Clin Pharmacol Drug Dev Nov 10 [Epub ahead of print].
13. Grotenhermen, F. 2003 Clinical pharmacokinetics of cannabinoids J Cannabis Therapeutics 3 1 3 50.
14. Grotenhermen, F. 2003 Pharmacokinetics and pharmacodynamics of cannabinoids Clin. Pharmacokinet 42 4 327 360.
15. Hložek, T. L. Uttl, L. Kadeřábek, M. Balíková, E. Lhotková, R. R. Horsley, P. Nováková, K Šíchová, K. Štefková, F Tylš, M Kuchař, and Páleníček T 2017 Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC Eur Neuropsychopharmacol 27 12 1223 1237.
16. Agurell, S., S. Carlsson, J. E. Lindgren, A. Ohlsson, H. Gillspie, and L. Hollister 1981 Interaction of THC with cannabinol and cannabidiol following oral administration in man Assay of cannabinol and cannabidiol by mass fragmentography Experientia 37 10 1090 1092.
17. Manini, A. F., G. Yiannoulos, M. M. Bergamaschi, S. Hernandez, R. Olmedo, A. J. Barnes, G. Winkel, R. Sinha, D. Jutras Aswad, M. A. Huestis and Y. I. Hurd 2015 Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans J Addict Med 9 3 204 210.
18. Ohlsson, A., J. Lindgren, and S. Andersson 1984 Single dose kinetics of cannabidiol in man Pp 219225 in The Cannabinoids Chemical, Pharmacologic, and Therapeutic Aspects 1 st Ed Academic Press, New York, 932 p.
19. Samara, E., M. Bialer, and R. Mechoulam 1988 Pharmacokinetics of cannabidiol in dogs Drugs Metab Dispos 16 3 469 472.
20. Zgair, A., J. Lee, J. C. Wong, P. M. Fischer, D. A. Barrett, C. S. Constantinescu, and P. Gershkovich 2015 Effect of long chain triglyceride formulation on the oral bioavailability of cannabidiol American Association of Pharmaceutical Scientists, Annual Meeting, Poster.
21. Kale et al.: Emulsion, Micro-emulsion and Nano Emulsion. Systematic Reviews in Pharmacy, Vol 8, Issue 1, Jan-Dec, 2017.
22. Bruni et al., Cannabinoid Delivery Systems for Pain and
Inflammation Treatment. Molecules 2018, 23, 2478;doi:10.3390/molecules23102478
23. Saudagar et al., Pharmaceutical Nano emulsion as a Rational Carrier for Drug Delivery. Research J. Pharm. and Tech. 9(3): Mar., 2016; Page 298-304